At its meeting on 08 August 2022 the Transparency Council adopted Opinion No. 121/2022 on the changes to the drug programme B.44 “Treatment of patients with severe asthma (ICD-10: J45, J82)”.
Publication with the minutes of the Transparency Council meeting